Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study |
Kang, Hye Jin
(Department of Radiation Oncology, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine)
Kay, Chul-Seung (Department of Radiation Oncology, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine) Son, Seok Hyun (Department of Radiation Oncology, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine) Kim, Myungsoo (Department of Radiation Oncology, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine) Jo, In Young (Department of Radiation Oncology, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine) Lee, So Jung (Department of Radiation Oncology, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine) Lee, Dong Hwan (Department of Urology, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine) Suh, Hong Jin (Department of Urology, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine) Choi, Yong Sun (Department of Urology, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine) |
1 | World Cancer Research Fund International. Worldwide data: world cancer statistics for the most common cancers [Internet]. London: World Cancer Research Fund International; c2015 [cited 2015 Aug 12]. Available from: http://www.wcrf.org/int/cancer-facts-figures/worldwide-data. |
2 | Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127-41. DOI |
3 | Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9. DOI |
4 | Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-6. DOI |
5 | Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014;15:464-73. DOI |
6 | Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. DOI |
7 | Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007;68:682-9. DOI |
8 | Ray KJ, Sibson NR, Kiltie AE. Treatment of breast and prostate cancer by hypofractionated radiotherapy: potential risks and benefits. Clin Oncol (R Coll Radiol) 2015;27:420-6. DOI |
9 | Tucker SL, Thames HD, Michalski JM, et al. Estimation of alpha/beta for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys 2011;81:600-5. DOI |
10 | Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dosefractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82:e17-24. DOI |
11 | National Comprehensive Cancer Network. NCCN guidelines for patients: prostate cancer [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2016 [cited 2016 Mar 17]. Available from: http://www.nccn.org/patients/guidelines/prostate/files/assets/common/downloads/files/prostate.pdf. |
12 | Proust-Lima C, Taylor JM, Secher S, et al. Confirmation of a low ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeatedmeasures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2011;79:195-201. DOI |
13 | Dolezel M, Odrazka K, Zouhar M, et al. Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer. Strahlenther Onkol 2015;191:338-46. DOI |
14 | Jani AB, Su A, Correa D, Gratzle J. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 2007;10:82-6. DOI |
15 | Arcangeli S, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:1172-8. DOI |
16 | Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:11-8. DOI |
17 | Huang EH, Pollack A, Levy L, et al. Late rectal toxicity: dosevolume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;54:1314-21. DOI |
18 | Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999;85:2460-8. DOI |
19 | Yeoh E, Horowitz M, Russo A, et al. Effect of pelvic irradiation on gastrointestinal function: a prospective longitudinal study. Am J Med 1993;95:397-406. DOI |
20 | Guckenberger M, Lawrenz I, Flentje M. Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT. Strahlenther Onkol 2014;190:48-53. DOI |
21 | Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124-9. DOI |
22 | Teh BS, Mai WY, Augspurger ME, et al. Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. Int J Radiat Oncol Biol Phys 2001;49:465-72. DOI |
23 | Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176(4 Pt 1):1415-9. DOI |